Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
News|Articles|January 27, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-02-04-2015
- Volume 11
- Issue 2
FUJIFILM Diosynth Begins Work on Bioprocess Innovation Center
Author(s)Pharmaceutical Technology Editors
The new facility will feature new research and development capabilities.
Advertisement
FUJIFILM Diosynth announced on Jan. 13, 2015 that the company is opening a new facility in Research Triangle Park, North Carolina. The new location, called the Bioprocess Innovation Center, will offers clients services in process invention and process and product characterization for its clients, according to a press release.
"The construction of this building reflects the continued commitment of our organization to provide our clients with the infrastructure to efficiently and innovatively bring their products to the clinic and beyond for the benefit of their patients," said Steve Bagshaw, CEO, FUJIFILM Diosynth Biotechnologies.
The three-story, 62,000-square-foot facility has an expected completion date in the fourth quarter of 2015.
Source:
Articles in this issue
over 11 years ago
New Excipient Options for Oral Solid Dosage Drugsover 11 years ago
Extending Shelf Life through Better Blister Package Designsover 11 years ago
More Growth Expected for API Custom Manufacturing in 2015over 11 years ago
Catalent Expands High-Potency Handling Capabilityover 11 years ago
PPD Announces Completion of Clinical Studies Facility in Irelandover 11 years ago
Ash Stevens to Manufacture Amotosalen APIover 11 years ago
SAFC Expands Irvine Facilityover 11 years ago
AMRI Acquires Two Aptuit FacilitiesAdvertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement